- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05209230
Is Myocardial Stunning Induced by Continuous Renal Replacement Therapy a Reality in Critically Ill Patients? (MS-CRRT)
Myocardial stunning during chronic intermittent hemodialysis is a well-described phenomenon. Little case series of patients presenting myocardial stunning during renal replacement therapy for acute kidney injury in critically ill patients are reported, with intermittent hemodialysis and continuous renal replacement therapy. However, the small sample sizes and the absence of a control arm limit their interpretation, mainly whether the myocardial stunning may be related to cardiac loading conditions variations and whether it may impact the hemodynamic.
The investigator hypothesize that myocardial stunning induced by renal replacement therapy is frequent, independent from cardiac loading conditions and associated with peripheral hypoperfusion.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: RUSTE Martin, MD, Msc
- Phone Number: +33472118956
- Email: martin.ruste@gmail.com
Study Contact Backup
- Name: JACQUET-LAGREZE Matthias, MD, Msc
- Email: Matthias.jacquet-lagreze@chu-lyon.fr
Study Locations
-
-
-
Bron, France, 69500
- Not yet recruiting
- Département d'anesthésie-réanimation Hôpital cardiologique Louis Pradel Groupe Hospitalier Est
-
Contact:
- RUSTE Martin, MD, Msc
- Phone Number: +33472118956
- Email: martin.ruste@gmail.com
-
Bron, France, 69500
- Recruiting
- Ruste Martin
-
Contact:
- RUSTE MARTIN, Dr
-
Lyon, France, 69008
- Recruiting
- Hopital Edourd Herriot
-
Contact:
- CROZON-CLAUZEL Jullien, Dr
- Email: jullien.crozon-clauzel@chu-lyon.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age > 18 years old
- Acute Kidney Injury grade 3 (KDIGO)
- Indication for renal replacement therapy for the clinician in charge
Exclusion Criteria:
- Emergency indication to renal replacement therapy (pH<7.15, Kaliemia > 6mmol/L, refractory pulmonary oedema)
- Poor echogenicity with speckle tracking analysis failure
- Chronic hemodialysis
- Extra corporeal membrane oxygenation, left ventricular assist device.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Continuous renal replacement therapy arm
Echocardiographic evaluation (with 2D speckle tracking analysis of left ventricular segmental function) 1 hour before and 3 hours after the initiation of continuous renal replacement therapy (continuous veno venous hemofiltration) initiation
|
Continuous renal replacement therapy (veno venous hemofiltration) without net ultrafiltration, through a dedicated central venous catheter
|
Other: Control arm
Two echocardiographic evaluations (with 2D speckle tracking analysis of left ventricular segmental function) at an interval of 4 hours, before the continuous renal replacement therapy initiation.
|
Continuous renal replacement therapy is differed from 6 hours to allowed 2 control echocardiographic evaluations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of segment of the left ventricle with regional wall motion abnormalities
Time Frame: Change between the echocardiography at baseline and the echocardiography 4 hours after.
|
Numbers of segments of the left ventricle (by patient) with a decrease greater than 20% of the peak systolic longitudinal strain (2D speckle tracking) on the second echocardiography as compared to baseline.
|
Change between the echocardiography at baseline and the echocardiography 4 hours after.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: RUSTE Martin, MD, Msc, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL21_1013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Stunning
-
Johns Hopkins UniversityNot yet recruitingMyocardial StunningUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...WithdrawnMyocardial Stunning
-
Tampere University HospitalTerminatedMyocardial StunningFinland
-
Tehran University of Medical SciencesRecruitingMyocardial Infarction | Myocardial Ischemia | Myocardial StunningIran, Islamic Republic of
-
University Hospital Inselspital, BerneFederal Office of Sports, SwitzerlandCompletedMyocardial Ischemia | Heart Failure | Exercise | Myocardial Stunning | Myocardial ContractionSwitzerland
-
Johns Hopkins UniversityWithdrawn
-
Vastra Gotaland RegionRecruiting
-
The First Affiliated Hospital of Dalian Medical...Nanfang Hospital of Southern Medical University; Beijing Anzhen Hospital; First...CompletedHibernation, Myocardial | Complete Occlusion of Coronary Artery
-
University Hospital, GenevaWithdrawnMyocardial Stunning | Transesophageal Echocardiography | Circulation, Extracorporeal
-
University Hospital, RouenBristol-Myers Squibb; GE Healthcare; Fédération Française de Cardiologie; Société... and other collaboratorsCompletedMyocardial Infarction | Myocardial Ischemia | Coronary Arteriosclerosis | Heart Failure, Congestive | Myocardial StunningFrance, Belgium
Clinical Trials on Continuous renal replacement therapy
-
Chulalongkorn UniversityCompletedAcute Renal FailureThailand
-
AKI Critical Care Research FoundationUnknownContinuous Renal Replacement TherapyUnited States
-
Sunnybrook Health Sciences CentreDialysis Solutions Inc.Completed
-
University of ThessalyRecruitingSepsis | Septic Shock | Renal Replacement Therapy | Aminoglycoside ToxicityGreece
-
Children's Hospital Medical Center, CincinnatiTerminatedAcute Kidney Injury | Fluid OverloadUnited States
-
Southwest Hospital, ChinaUnknown
-
Ziekenhuis Netwerk Antwerpen (ZNA)TerminatedRenal Replacement Therapy | Renal Insufficiency, AcuteBelgium
-
Southeast University, ChinaBaxter Healthcare CorporationCompletedAcute Kidney Injury Due to Sepsis (Disorder)China
-
Johannes Gutenberg University MainzWithdrawnSeptic Shock | Severe SepsisGermany
-
University Hospital MuensterBaxter Healthcare CorporationRecruitingInfections | Critically Ill | Continuous Renal Replacement TherapyGermany, Austria, Brazil